Why the Pfizer-BioNTech vaccine is no cure for all coronavirus ills


Freak accident results in death of…
Ng loves to run despite knee injury
Crazy Rich Asians’ Jon M. Chu To Direct Lilo…
Even Covid-19 can’t keep K-pop down…
PropertyGuru’s Virtual Expo Just Ra…
SpaceX’s Crew-1 astronaut launch for…
PlayStation 5 Bugs and Glitches (With Fixes)…
Singapore minister says mega trade deal…
Ready to Sweat? These 5 Instagram and…
Jordan Pickford not to blame for Belgium
Volvo’s ‘Most Extreme’ Crash Test Involves a…
Officials found 1,500 fraudulent votes that…
Chinese stand-up comedy gets a shot in…
Asia reaches crossroads in fight against…
PS Plus Is The Only Way For PS5 Owners…
Oil Climbs With U.S. Ruling Out Lockdown
Vaccine scientist hopes for return to ‘normal’…
Liverpool hit with new injury scare
Hyundai Motor Group to launch NVIDIA
Key West residents voted to ban large…
Should SG swallow cost of migrant workers’…
PM Lee calls RCEP agreement a “major…
Jennifer Lopez calls for unity in powerful…
SG’s walking trails with food stops
AP FACT CHECK: Trump’s bogus claims…
Samsung’s new Smart Monitor is like a TV…
MAS advisory panel urges financial …
Wendy’s Is Bringing Back This Popular…
These Drumstick Mini Drums Are Perfect For…
Harry Kane’s new, deeper role under…
More wealthy travelers are turning to private…
The New S$868 Surface Laptop Go Is Here To…
Singapore signs world’s largest FTA
Jewel forever grateful to Beyonce for not…
Men need to open up about mental health…
Son Heung-min Covid scare as outbreak hits…
Watch live at 9 pm ET: NASA, SpaceX Crew-1…
The Week In Games: Hyrule Warriors: Age…
Asian shares climb after S&P 500 record…
What The Crown Gets Right & Wrong About…
Roker Report Brainbusters: Can you…
Freak accident results in death of 7-year-old-boy at the hands of his…
Ng loves to run despite knee injury
The coronavirus vaccine developed by Pfizer and BioNTech has raised hopes for the end of the pandemic after the interim result of trials showed 90 per cent effectiveness, but questions remain about safety, distribution and its precise effect on the virus.
Before the vaccine is approved for use by health authorities around the world, it will have to meet certain safety requirements that vary by jurisdiction.
In the United States, the Food and Drug Administration is requiring manufacturers to produce safety data on half of subjects for two months after their second dose of the vaccine before it can be approved for emergency use.
Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China.
Pfizer has said it expects to reach this by the third week of November, and has reported no serious adverse reactions in the nearly 40,000 trial participants who have received two doses of the vaccine.
The US multinational believes it can produce 50 million vaccine doses this year and up to 1.3 billion doses in 2021.
Video player from: YouTube (Privacy Policy, Terms)
Ian Frazer, a professor at the University of Queensland who co-invented the human papillomavirus vaccine, said there was still a “small risk of unexpected safety issues” and that some people might refuse to take it.
“It depends on their risk level – I’d have it if working in a hospital,” he said. “I’d guess that most young people will think twice in Australia where there’s now no virus.”
Terry Nolan, a vaccine expert at the University of Melbourne, said that while he found safety concerns about such a rapidly developed vaccine “understandable”, it would be vital for the public to get on board with mass immunisation.
“Unless there are very high levels of protection of the community there’s very little hope of getting anything near herd immunity,” Nolan said.
Apart from safety, potential complications could include virus mutations that could impact the vaccine’s effectiveness over time.
Health authorities across the world have indicated that the first doses of a successful vaccine will go to high-risk groups, such as frontline health care workers, employees in aged care facilities, and the elderly.
Frazer predicted the general public would have to wait a “year or longer” until they would have access to the vaccine.
Nolan suggested a less conservative time frame, saying he expected a vaccine to be available “well before” a year’s time.
Video player from: YouTube (Privacy Policy, Terms)
He said Pfizer’s apparent breakthrough indicated that other vaccines based on the same principles would also be effective, which would be a “matter of comfort for the world that the supply from a number of manufacturers is very likely to be there”.
Nearly a dozen vaccines are in large-scale, human trials – known as phase 3 trials – including candidates developed in the US, China, Russia and Britain.
In August, Russia became the first country to announce the approval of a vaccine before the completion of extensive human trials, prompting widespread scepticism and criticism among scientists and medical professionals. The Russian government later said the approval of the vaccine, developed by the Moscow-affiliated Gamaleya Institute, was “conditional” on the results of phase 3 trials. Last month, Russian President Vladimir Putin announced the approval of a second vaccine before phase 3 trials had even begun.
China has approved the limited use of three vaccines for some groups such as the military, including the Sinovac Biotech vaccine, trials for which were briefly halted by Brazilian authorities on Monday following an “adverse event”. Brazil’s health authority restarted the trials on Wednesday after it was confirmed that a volunteer had died from suicide, not an adverse reaction to the vaccine. Chinese health officials have reported no adverse side effects from the hundreds of thousands of doses administered through the emergency use listing of the Sinovac vaccine and vaccines by CanSino Biologics and the Wuhan Institute of Biological Products.
Governments around the world have invested huge sums into securing multiple different vaccines ahead of time, with the cost per dose ranging from US$32-US$37 for the Moderna vaccine to a few dollars for AstraZeneca’s offering. The US government paid US$1.5 billion to Moderna alone to secure 100 million doses of its candidate.
The buying up of potential vaccines by rich countries has raised concerns about their availability in the developing world.
As of September, developed countries including the US, Britain, Australia and Japan had secured more than half of the 5.3 billion doses allocated in supply deals inked by AstraZeneca, the Gamaleya Institute, Moderna, Pfizer and Sinovac, according to an analysis by Ofxam.
In response to such concerns, the global collaboration Covax has raised more than US$2 billion from nearly 100 rich nations to purchase and distribute vaccines among poorer countries.
Distribution poses a major challenge due to the particular storage requirements of the vaccine, particularly in lower-income countries with less developed infrastructure. Unlike most vaccines which can be stored in a normal refrigerator, the Pfizer/BioNTech vaccine must be kept at -80 degrees Celsius. Freezers capable of maintaining such temperatures are uncommon even at major hospitals in developed countries. Pfizer has said it plans to use dry ice to transport the vaccine by land and air to distribution centres around the world, a daunting logistical feat.
Video player from: YouTube (Privacy Policy, Terms)
“Are there sufficient ultra-low (temperature) refrigerators at vaccination sites?” asked John Siu Lun Tam, a vaccination expert at the Hong Kong Polytechnic University. “How would we know if the ‘ultra-low cold chain’ had been kept and that the vaccine you get is not inactivated?
“The complete vaccinations process requires two injections,” Tam said. “There will be a logistics issue about how to make sure people actually get two doses.”
A big unknown remains the vaccine’s effectiveness in stopping transmission of the virus. While the Pfizer/BioNTech candidate has shown major promise in preventing sickness, there is as yet little indication it is effective at stopping the spread of infection among people.
“The animal studies which have been done ahead of time so far, including some challenge studies in monkeys, suggest that this class of vaccine may not prevent transmission,” Nolan said.
That could result in authorities significantly prolonging their pandemic restrictions. Plans for unrestricted international travel for those with a “health passport” showing they have been vaccinated, for example, might have to wait.
“The whole quarantine business is very, very difficult,” Nolan said. “To have completely free travel for those who have, say, a passport, would be what we’re hoping to happen, but we can’t at the moment guarantee that would happen.”
This article originally appeared on the South China Morning Post (www.scmp.com), the leading news media reporting on China and Asia.
Copyright (c) 2020. South China Morning Post Publishers Ltd. All rights reserved.
Millionaire MENSA Trader’s Top Weekly Picks
Launch obd2 scanner